Clinical trial
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
NCT01728805 · Kyowa Kirin, Inc., Industry · Completed
Key facts
| NCT number | NCT01728805 |
|---|---|
| Title | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL |
| Official title | Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma |
| Lead sponsor | Kyowa Kirin, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cutaneous T-Cell Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | KW-0761, Vorinostat |
| Enrollment | 372 |
| Start date | Nov 1, 2012 |
| Primary completion | Mar 1, 2017 |
| Completion | Feb 17, 2021 |
| First posted | Nov 20, 2012 |
| Last update posted | Apr 25, 2024 |
| Countries | Australia, Denmark, France, Germany, Italy, Japan, Netherlands, Spain, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: